上海醫藥(02607.HK)擬與九洲藥業設立合資公司
格隆匯 8 月 28日丨上海醫藥(02607.HK)公佈,為進一步提升公司製劑板塊市場競爭力,上海醫藥與九洲藥業達成共識,雙方於2020年8月28日簽署《合作設立公司協議》,在浙江省台州市設立合資公司,形成長期戰略合作關係。
合資公司名稱暫定為:浙江上藥九洲生物製藥有限公司(暫定名,具體名稱以工商行政管理部門最終核定為準),註冊資本為人民幣5億元,合資雙方均以貨幣形式出資,其中公司認繳出資人民幣22,500萬元,佔合資公司45%股權。九洲藥業認繳出資人民幣22,500萬元,佔合資公司45%股權;股權激勵平台認繳出資人民幣5,000萬元,佔合資公司10%股權。
公告稱,此次上海醫藥與九洲藥業本着資源共享、優勢互補、互利互惠、長遠戰略合作的原則,在浙江台州設立合資公司,將充分利用雙方在原料藥和製劑業務領域的研發、註冊、生產及銷售優勢,共同合作開發高端仿製藥及改良型新藥,推動MAH制度在合資公司落地,從而進一步釋放公司高端製劑產能及豐富產品品類,同時通過與上游原料藥優質供應商的深度戰略合作,保障公司在產及在研製劑產品的原料藥供應,提升產品的市場競爭力,推動產品的國際化認證及國際市場開拓,實現公司醫藥工業板塊業務的持續穩定增長,符合公司長期發展戰略。由於合資公司尚未設立,目前尚無法預測上述投資可能對公司未來財務狀況和經營成果的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.